Handok Pharmaceuticals Co., Ltd.   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Seoul Korea, Republic of (1954)
Status: No NME R&D (1954)

Organization Overview

First Clinical Trial
2005
NCT00261079
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Handok Inc. | Handok Pharmaceuticals Co., Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cryopyrin-Associated Periodic Syndromes (Phase 2)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Digestive System Neoplasms (Phase 1)

Essential Hypertension (Phase 2)

Gastrointestinal Neoplasms (Phase 1)

Hyperplasia (Phase 4)

Hypertension (Phase 2)

Neoplasms (Phase 1)

Osteoarthritis (Phase 3)

Prostatic Hyperplasia (Phase 4)

Pruritus (Phase 4)

Psychotic Disorders (Phase 4)

Rhinitis (Phase 4)

Rhinitis, Allergic (Phase 4)

Schizophrenia (Phase 4)

Skin Diseases (Phase 4)

Syndrome (Phase 2)

Urinary Bladder Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 40
  • # of Trial APIs: 27